| 1 |
Fuxman C, Sicilia B, Linares ME, García-López S, González Sueyro R, González-Lamac Y, Zabana Y, Hinojosa J, Barreiro de Acosta M, Balderramo D, Balfour D, Bellicoso M, Daffra P, Morelli D, Orsi M, Rausch A, Ruffinengo O, Toro M, Sambuelli A, Novillo A, Gomollón F, De Paula JA. GADECCU 2022 Guideline for the treatment of Ulcerative Colitis. Adaptation and updating of the GETECCU 2020 Guideline. Gastroenterol Hepatol 2023:S0210-5705(23)00014-6. [PMID: 36731724 DOI: 10.1016/j.gastrohep.2023.01.009] [Reference Citation Analysis]
|
| 2 |
Ueno N, Sugiyama Y, Kobayashi Y, Murakami Y, Iwama T, Sasaki T, Kunogi T, Sakatani A, Takahashi K, Tanaka K, Serikawa S, Ando K, Kashima S, Muto M, Inaba Y, Moriichi K, Tanabe H, Okumura T, Fujiya M. Concomitant pharmacologic medications influence the clinical outcomes of granulocyte and monocyte adsorptive apheresis in patients with ulcerative colitis: A multicenter retrospective cohort study. J Clin Apher 2023. [PMID: 36636880 DOI: 10.1002/jca.22040] [Reference Citation Analysis]
|
| 3 |
Masi L, Ciuffini C, Petito V, Pisani LF, Lopetuso LR, Graziani C, Pugliese D, Laterza L, Puca P, Di Vincenzo F, Pizzoferrato M, Napolitano D, Turchini L, Amatucci V, Schiavoni E, Privitera G, Minordi LM, Mentella MC, Papa A, Armuzzi A, Gasbarrini A, Scaldaferri F. Innovative, complementary and alternative therapy in inflammatory bowel diseases: A broad 2020s update. Front Gastroenterol 2022;1. [DOI: 10.3389/fgstr.2022.1022530] [Reference Citation Analysis]
|
| 4 |
Bamias G, Zampeli E, Domènech E. Targeting neutrophils in inflammatory bowel disease: revisiting the role of adsorptive granulocyte and monocyte apheresis. Expert Rev Gastroenterol Hepatol 2022;16:721-35. [PMID: 35833363 DOI: 10.1080/17474124.2022.2100759] [Reference Citation Analysis]
|
| 5 |
Yasmin F, Najeeb H, Naeem U, Moeed A, Koritala T, Surani S. Apheresis: A cell-based therapeutic tool for the inflammatory bowel disease. World J Clin Cases 2022; 10(21): 7195-7208 [DOI: 10.12998/wjcc.v10.i21.7195] [Reference Citation Analysis]
|
| 6 |
Torzewski J, Brunner P, Ries W, Garlichs CD, Kayser S, Heigl F, Sheriff A. Targeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons. J Clin Med 2022;11:1771. [PMID: 35407379 DOI: 10.3390/jcm11071771] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 7 |
Vasile Balaban D, Jinga M. Apheresis in Inflammatory Bowel Disease: Current Evidence. Crohn’s Disease Recent Advances 2021. [DOI: 10.5772/intechopen.93605] [Reference Citation Analysis]
|
| 8 |
Raine T, Verstockt B, Kopylov U, Karmiris K, Goldberg R, Atreya R, Burisch J, Burke J, Ellul P, Hedin C, Holubar SD, Katsanos K, Lobaton T, Schmidt C, Cullen G. ECCO Topical Review: Refractory Inflammatory Bowel Disease. J Crohns Colitis 2021;15:1605-20. [PMID: 34160593 DOI: 10.1093/ecco-jcc/jjab112] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 9 |
Ueno N, Sugiyama Y, Kobayashi Y, Murakami Y, Iwama T, Sasaki T, Kunogi T, Takahashi K, Tanaka K, Ando K, Kashima S, Inaba Y, Moriichi K, Tanabe H, Taruishi M, Saitoh Y, Okumura T, Fujiya M. Fecal calprotectin is a useful biomarker for predicting the clinical outcome of granulocyte and monocyte adsorptive apheresis in ulcerative colitis patients: a prospective observation study. BMC Gastroenterol 2021;21:316. [PMID: 34362299 DOI: 10.1186/s12876-021-01889-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Sicilia B, García-López S, González-Lama Y, Zabana Y, Hinojosa J, Gomollón F; Grupo Español de Trabajo de Enfermedad de Crohn., Colitis Ulcerosa o Spanish Group for Working on Crohn's Disease and Ulcerative Colitis (GETECCU). GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach. Gastroenterol Hepatol 2020;43 Suppl 1:1-57. [PMID: 32807301 DOI: 10.1016/j.gastrohep.2020.07.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 11 |
Woźniak M, Kurnatowska I, Małecka-Panas E, Talar-Wojnarowska R. Leukocytapheresis in patients with inflammatory bowel diseases. Prz Gastroenterol 2021;6:99-105. [PMID: 34276835 DOI: 10.5114/pg.2021.106658] [Reference Citation Analysis]
|
| 12 |
Kiss S, Németh D, Hegyi P, Földi M, Szakács Z, Erőss B, Tinusz B, Hegyi PJ, Sarlós P, Alizadeh H. Granulocyte and monocyte apheresis as an adjunctive therapy to induce and maintain clinical remission in ulcerative colitis: a systematic review and meta-analysis. BMJ Open 2021;11:e042374. [PMID: 34011580 DOI: 10.1136/bmjopen-2020-042374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 13 |
Domènech E, Grífols JR, Akbar A, Dignass AU. Use of granulocyte/monocytapheresis in ulcerative colitis: A practical review from a European perspective. World J Gastroenterol 2021; 27(10): 908-918 [PMID: 33776362 DOI: 10.3748/wjg.v27.i10.908] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 14 |
Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 89] [Cited by in F6Publishing: 78] [Article Influence: 44.5] [Reference Citation Analysis]
|
| 15 |
Jentzer A, Veyrard P, Roblin X, Saint-Sardos P, Rochereau N, Paul S, Bourlet T, Pozzetto B, Pillet S. Cytomegalovirus and Inflammatory Bowel Diseases (IBD) with a Special Focus on the Link with Ulcerative Colitis (UC). Microorganisms 2020;8:E1078. [PMID: 32698383 DOI: 10.3390/microorganisms8071078] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 16 |
Chen XL, Mao JW, Wang YD. Selective granulocyte and monocyte apheresis in inflammatory bowel disease: Its past, present and future. World J Gastrointest Pathophysiol 2020; 11(3): 43-56 [PMID: 32435521 DOI: 10.4291/wjgp.v11.i3.43] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 17 |
Li N, Mao J, Tang H, Zhu L, Tan X, Bi J, Wu H, Chen X, Wang Y. Efficacy and safety of adsorptive granulomonocytapheresis in Chinese patients with ulcerative colitis: A retrospective analysis of 50 cases with focus on factors impacting clinical efficacy. J Clin Apher 2020;35:271-80. [PMID: 32378240 DOI: 10.1002/jca.21787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 18 |
Farrell D, Artom M, Czuber-Dochan W, Jelsness-Jørgensen LP, Norton C, Savage E. Interventions for fatigue in inflammatory bowel disease. Cochrane Database Syst Rev 2020;4:CD012005. [PMID: 32297974 DOI: 10.1002/14651858.CD012005.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 19 |
Naganuma M, Yokoyama Y, Motoya S, Watanabe K, Sawada K, Hirai F, Yamamoto T, Hanai H, Omori T, Kanai T, Hibi T; CAPTAIN study Group. Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial. J Gastroenterol 2020;55:390-400. [PMID: 31811562 DOI: 10.1007/s00535-019-01651-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 20 |
Okabayashi S, Kobayashi T, Hibi T. Inflammatory Bowel Disease in Japan-Is It Similar to or Different from Westerns? J Anus Rectum Colon 2020;4:1-13. [PMID: 32002471 DOI: 10.23922/jarc.2019-003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 21 |
Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019;34:171-354. [PMID: 31180581 DOI: 10.1002/jca.21705] [Cited by in Crossref: 539] [Cited by in F6Publishing: 565] [Article Influence: 134.8] [Reference Citation Analysis]
|
| 22 |
. UEG Week 2019 Poster Presentations. United European Gastroenterol J 2019;7:189-1030. [PMID: 32213001 DOI: 10.1177/2050640619854671] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 23 |
Rodríguez-Lago I, Benítez JM, Sempere L, Sáez-González E, Barreiro-de Acosta M, de Zárate JO, Cabriada JL. The combination of granulocyte-monocyte apheresis and vedolizumab: A new treatment option for ulcerative colitis? J Clin Apher 2019;34:680-5. [PMID: 31518013 DOI: 10.1002/jca.21746] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 24 |
Kruis W, Nguyen P, Morgenstern J, Ramlow W, Dignaß A, Stallmach A, Drebber U. Novel Leucocyte/Thrombocyte Apheresis for Induction of Steroid-Free Remission in Ulcerative Colitis: A Controlled Randomized Pilot Study. J Crohns Colitis 2019;13:949-53. [PMID: 30863856 DOI: 10.1093/ecco-jcc/jjz005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 25 |
Fakhreddine AY, Frenette CT, Konijeti GG. A Practical Review of Cytomegalovirus in Gastroenterology and Hepatology. Gastroenterol Res Pract. 2019;2019:6156581. [PMID: 30984257 DOI: 10.1155/2019/6156581] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 26 |
Motoya S, Watanabe K, Ogata H, Kanai T, Matsui T, Suzuki Y, Shikamura M, Sugiura K, Oda K, Hori T, Araki T, Watanabe M, Hibi T. Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. PLoS One 2019;14:e0212989. [PMID: 30807613 DOI: 10.1371/journal.pone.0212989] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 27 |
Whaley KG, Rosen MJ. Contemporary Medical Management of Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:56-66. [PMID: 29889235 DOI: 10.1093/ibd/izy208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 28 |
Saniabadi AR, Tanaka T, Yamamoto T, Kruis W, Sacco R. Granulomonocytapheresis as a cell-dependent treatment option for patients with inflammatory bowel disease: Concepts and clinical features for better therapeutic outcomes. J Clin Apher. 2019;34:51-60. [PMID: 30407662 DOI: 10.1002/jca.21670] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 29 |
UEG Week 2018 Poster Presentations. United European Gastroenterol j 2018;6. [DOI: 10.1177/2050640618792819] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 30 |
Mezzina N, Campbell Davies SE, Ardizzone S. Nonbiological therapeutic management of ulcerative colitis. Expert Opinion on Pharmacotherapy 2018;19:1747-57. [DOI: 10.1080/14656566.2018.1525361] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 31 |
Kobayashi K, Suzuki Y, Watanabe K, Oda K, Mukae M, Yamada A, Yamagami H, Nishimura A, Okamoto H. A Phase 1, Multiple-Dose Study of Vedolizumab in Japanese Patients With Ulcerative Colitis. J Clin Pharmacol 2019;59:271-9. [PMID: 30192378 DOI: 10.1002/jcph.1307] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 32 |
Yamamoto T, Iida T, Ikeya K, Kato M, Matsuura A, Tamura S, Takano R, Tani S, Osawa S, Sugimoto K, Shimoyama T, Hanai H. A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis. Clin Transl Gastroenterol. 2018;9:170. [PMID: 29977035 DOI: 10.1038/s41424-018-0037-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 33 |
Dignass A, Akbar A, Baumgart DC, Bommelaer G, Bouguen G, Cadiot G, Gillessen A, Grimaud JC, Hart A, Hoque S, Makins R, Michiels C, Moreau J, Premchand P, Ramlow W, Schanz S, Subramanian S, von Tirpitz C, Bonaz B. Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis. Scand J Gastroenterol 2018;53:442-8. [PMID: 29513111 DOI: 10.1080/00365521.2018.1447598] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 34 |
Yokoyama Y, Kamikozuru K, Watanabe K, Nakamura S. Inflammatory bowel disease patients experiencing a loss of response to infliximab regain long-term response after undergoing granulocyte/monocyte apheresis: A case series. Cytokine 2018;103:25-8. [DOI: 10.1016/j.cyto.2017.12.030] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 35 |
Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol 2018;53:305-53. [PMID: 29429045 DOI: 10.1007/s00535-018-1439-1] [Cited by in Crossref: 281] [Cited by in F6Publishing: 281] [Article Influence: 56.2] [Reference Citation Analysis]
|
| 36 |
Rolandsdotter H, Eberhardson M, Fagerberg UL, Finkel Y. Granulocyte and Monocyte Apheresis for Induction of Remission in Children With New-Onset Inflammatory Bowel Colitis. J Pediatr Gastroenterol Nutr 2018;66:84-9. [PMID: 28604509 DOI: 10.1097/MPG.0000000000001641] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 37 |
Imperiali G, Amato A, Terpin MM, Beverina I, Bortoli A, Devani M, Viganò C; Study Group on IBD (GSMII) . Granulocyte-Monocyte Apheresis in Steroid-Dependent, Azathioprine-Intolerant/Resistant Moderate Ulcerative Colitis: A Prospective Multicenter Study. Gastroenterol Res Pract 2017;2017:9728324. [PMID: 29403531 DOI: 10.1155/2017/9728324] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 38 |
Lai YM, Yao WY, He Y, Jiang X, Gu YB, Chen MH, Liu YL, Yuan YZ, Qian JM. Adsorptive Granulocyte and Monocyte Apheresis in the Treatment of Ulcerative Colitis: The First Multicenter Study in China. Gut Liver. 2017;11:216-225. [PMID: 27843131 DOI: 10.5009/gnl15408] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 39 |
Kanekura T, Seishima M, Honma M, Etou T, Eto H, Okuma K, Okubo Y, Yamaguchi Y, Kambara T, Mabuchi T, Suga Y, Morita A, Yamanishi K, Tsuruta D, Itoh K, Yamaji K, Ikeda S. Therapeutic depletion of myeloid lineage leukocytes by adsorptive apheresis for psoriatic arthritis: Efficacy of a non-drug intervention for patients refractory to pharmacologics. J Dermatol 2017;44:1353-9. [DOI: 10.1111/1346-8138.13975] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 40 |
Tanaka T, Yamamoto T, Sawada K, Sacco R. Treatment options for children and adolescents with inflammatory bowel disease: is granulomonocytapheresis an effective alternative to drug therapy? Expert Rev Gastroenterol Hepatol 2017;11:749-58. [PMID: 28612637 DOI: 10.1080/17474124.2017.1341309] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 41 |
Nomura O, Osada T, Shibuya T, Ishikawa D, Haga K, Kodani T, Sakamoto N, Ogihara T, Yamaji K, Watanabe S. Efficacy of cytapheresis for remission induction and dermatological manifestations of ulcerative colitis. J Clin Apher. 2018;33:21-28. [PMID: 28581039 DOI: 10.1002/jca.21555] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 42 |
Sáez-González E, Moret I, Alvarez-Sotomayor D, Díaz-Jaime FC, Cerrillo E, Iborra M, Nos P, Beltrán B. Immunological Mechanisms of Adsorptive Cytapheresis in Inflammatory Bowel Disease. Dig Dis Sci 2017;62:1417-25. [PMID: 28432476 DOI: 10.1007/s10620-017-4577-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 43 |
Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016;31:149-162. [PMID: 27322218 DOI: 10.1002/jca.21470] [Cited by in Crossref: 197] [Cited by in F6Publishing: 306] [Article Influence: 32.8] [Reference Citation Analysis]
|
| 44 |
Muthas D, Reznichenko A, Balendran CA, Böttcher G, Clausen IG, Kärrman Mårdh C, Ottosson T, Uddin M, MacDonald TT, Danese S, Berner Hansen M. Neutrophils in ulcerative colitis: a review of selected biomarkers and their potential therapeutic implications. Scand J Gastroenterol 2017;52:125-35. [PMID: 27610713 DOI: 10.1080/00365521.2016.1235224] [Cited by in Crossref: 99] [Cited by in F6Publishing: 103] [Article Influence: 16.5] [Reference Citation Analysis]
|
| 45 |
Kanai T. Leukocytapheresis Therapy of Inflammatory Bowel Disease. Crohn's Disease and Ulcerative Colitis 2017. [DOI: 10.1007/978-3-319-33703-6_49] [Reference Citation Analysis]
|
| 46 |
Naganuma M, Mizuno S, Nanki K, Sugimoto S, Kanai T. Recent trends and future directions for the medical treatment of ulcerative colitis. Clin J Gastroenterol 2016;9:329-36. [DOI: 10.1007/s12328-016-0686-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 47 |
Dignass A, Akbar A, Hart A, Subramanian S, Bommelaer G, Baumgart DC, Grimaud JC, Cadiot G, Makins R, Hoque S, Bouguen G, Bonaz B. Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results. J Crohns Colitis 2016;10:812-20. [PMID: 26818659 DOI: 10.1093/ecco-jcc/jjw032] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 48 |
Samaan MA, Irving PM. The impact of updated NICE guidelines on biologic treatment of ulcerative colitis: reflections on past practices, the changing present and implications for the future. Expert Opin Biol Ther 2016;16:975-7. [PMID: 27186809 DOI: 10.1080/14712598.2016.1189529] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 49 |
Contini P, Negrini S, Bodini G, Trucchi C, Ubezio G, Strada P, Savarino V, Ghio M. Granulocytes and monocytes apheresis induces upregulation of TGFβ1 in patients with active ulcerative colitis: A possible involvement of soluble HLA-I. J Clin Apher 2017;32:49-55. [PMID: 27080173 DOI: 10.1002/jca.21466] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 50 |
Nakase H, Herfarth H. Cytomegalovirus Colitis, Cytomegalovirus Hepatitis and Systemic Cytomegalovirus Infection: Common Features and Differences. Inflamm Intest Dis 2016;1:15-23. [PMID: 27243020 DOI: 10.1159/000443198] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 51 |
Tian LL, Liu LN. Current approaches to management of ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2016; 24(7): 1054-1063 [DOI: 10.11569/wcjd.v24.i7.1054] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 52 |
Saito H, Hanafusa N, Kishikawa J, Noiri E, Sunami E, Ishihara S, Watanabe T, Nangaku M. Ulcerative colitis with hepatitis B virus infection treated successfully by granulocyte monocyte apheresis. J Clin Apher 2016;31:584-6. [PMID: 26876484 DOI: 10.1002/jca.21450] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 53 |
Pillet S, Pozzetto B, Roblin X. Cytomegalovirus and ulcerative colitis: Place of antiviral therapy. World J Gastroenterol 2016; 22(6): 2030-2045 [PMID: 26877608 DOI: 10.3748/wjg.v22.i6.2030] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 61] [Article Influence: 8.1] [Reference Citation Analysis]
|
| 54 |
Leitner GC, Vogelsang H. Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults. World J Gastrointest Pharmacol Ther 2016; 7(1): 5-20 [PMID: 26855808 DOI: 10.4292/wjgpt.v7.i1.5] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 55 |
Edfors K, Ståhlberg D, Söderman C. Retrospective Single Center Study of Granulocyte Monocyte Adsorption Apheresis Treatment in Inflammatory Bowel Disease. Ther Apher Dial 2016;20:79-85. [PMID: 26841133 DOI: 10.1111/1744-9987.12336] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 56 |
Ghosh S, Iacucci M. Acute severe ulcerative colitis. Gastrointestinal emergencies 2016. [DOI: 10.1002/9781118662915.ch34] [Reference Citation Analysis]
|
| 57 |
Hashiguchi K, Takeshima F, Akazawa Y, Matsushima K, Minami H, Machida H, Yamaguchi N, Shiozawa K, Ohba K, Ohnita K, Ichikawa T, Isomoto H, Nakao K. Advantages of fecal lactoferrin measurement during granulocyte and monocyte adsorptive apheresis therapy in ulcerative colitis. Digestion 2015;91:208-17. [PMID: 25823500 DOI: 10.1159/000375301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 58 |
Moreau J, Mas E. Drug resistance in inflammatory bowel diseases. Curr Opin Pharmacol. 2015;25:56-61. [PMID: 26645664 DOI: 10.1016/j.coph.2015.11.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 59 |
Tanida S, Mizoshita T, Ozeki K, Katano T, Kataoka H, Kamiya T, Joh T. Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2. World J Gastroenterol 2015; 21(29): 8776-8786 [PMID: 26269667 DOI: 10.3748/wjg.v21.i29.8776] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 60 |
Takayama T, Okamoto S, Hisamatsu T, Naganuma M, Matsuoka K, Mizuno S, Bessho R, Hibi T, Kanai T. Computer-Aided Prediction of Long-Term Prognosis of Patients with Ulcerative Colitis after Cytoapheresis Therapy. PLoS One 2015;10:e0131197. [PMID: 26111148 DOI: 10.1371/journal.pone.0131197] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 61 |
Ferrer Márquez M, Hernández Martínez Á, Reina Duarte Á, Rosado Cobián R. Current Status of the Treatment of Fulminant Colitis. Cirugía Española (English Edition) 2015;93:276-282. [DOI: 10.1016/j.cireng.2014.09.009] [Reference Citation Analysis]
|
| 62 |
Fowler S, Jones J, Hull PR, Ghosh S. Extracorporeal photopheresis for the treatment of Crohn's disease. Transfusion and Apheresis Science 2015;52:183-6. [DOI: 10.1016/j.transci.2015.02.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 63 |
Yokoyama Y, Watanabe K, Ito H, Nishishita M, Sawada K, Okuyama Y, Okazaki K, Fujii H, Nakase H, Masuda T, Fukunaga K, Andoh A, Nakamura S. Factors associated with treatment outcome, and long-term prognosis of patients with ulcerative colitis undergoing selective depletion of myeloid lineage leucocytes: a prospective multicenter study. Cytotherapy. 2015;17:680-688. [PMID: 25804800 DOI: 10.1016/j.jcyt.2015.02.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 64 |
Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, d'Haens G, d'Hoore A, Mantzanaris G, Novacek G, Öresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, van Assche G. [Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (Spanish version)]. Rev Gastroenterol Mex 2015;80:32-73. [PMID: 25769217 DOI: 10.1016/j.rgmx.2014.10.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 65 |
Sacco R, Tanaka T, Yamamoto T, Bresci G, Saniabadi AR. Adacolumn leucocytapheresis for ulcerative colitis: clinical and endoscopic features of responders and unresponders. Expert Rev Gastroenterol Hepatol 2015;9:327-33. [PMID: 25160857 DOI: 10.1586/17474124.2014.953060] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 66 |
Ferrer Márquez M, Hernández Martínez Á, Reina Duarte Á, Rosado Cobián R. Current Status of the Treatment of Fulminant Colitis. Cir Esp 2015;93:276-82. [PMID: 25649534 DOI: 10.1016/j.ciresp.2014.09.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 67 |
Schulze H, Esters P, Dignass A. Letter: leucocytapheresis as a nonpharmacologic treatment for patients with ulcerative colitis during pregnancy - authors' reply. Aliment Pharmacol Ther 2015;41:235-6. [PMID: 25511774 DOI: 10.1111/apt.13031] [Reference Citation Analysis]
|
| 68 |
Osada T, Watanabe S. Current Treatment Options for Inflammatory Bowel Diseases and Future Perspectives. Juntendo Medical Journal 2015;61:588-596. [DOI: 10.14789/jmj.61.588] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 69 |
De Cassan C, Savarino E, Marson P, Tison T, Hatem G, Sturniolo GC, D’Incà R. Granulo-monocyto apheresis is more effective in mild ulcerative colitis than in moderate to severe disease. World J Gastroenterol 2014; 20(45): 17155-17162 [PMID: 25493030 DOI: 10.3748/wjg.v20.i45.17155] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 70 |
Yokoyama Y, Matsuoka K, Kobayashi T, Sawada K, Fujiyoshi T, Ando T, Ohnishi Y, Ishida T, Oka M, Yamada M, Nakamura T, Ino T, Numata T, Aoki H, Sakou J, Kusada M, Maekawa T, Hibi T. A large-scale, prospective, observational study of leukocytapheresis for ulcerative colitis: treatment outcomes of 847 patients in clinical practice. J Crohns Colitis 2014;8:981-91. [PMID: 24556083 DOI: 10.1016/j.crohns.2014.01.027] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 71 |
Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating inflammatory bowel disease by adsorptive leucocytapheresis: A desire to treat without drugs. World J Gastroenterol 2014; 20(29): 9699-9715 [PMID: 25110409 DOI: 10.3748/wjg.v20.i29.9699] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 72 |
Gomollón F, García-López S, Sicilia B, Gisbert JP, Hinojosa J; en representació del Grupo Espa˜nol de Trabajode Enfermedad de Crohn y Colitis Ulcerosa or Spanish Group for Working on Crohn’sDisease and Ulcerative Colitis (GETECCU). [Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU]. Gastroenterol Hepatol 2013;36:e1-47. [PMID: 24215088 DOI: 10.1016/j.gastrohep.2012.11.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 73 |
Aceituno M, Zabana Y, Esteve M. [Treatment of severe ulcerative colitis flares]. Gastroenterol Hepatol 2014;37:471-9. [PMID: 25015428 DOI: 10.1016/j.gastrohep.2014.05.005] [Reference Citation Analysis]
|
| 74 |
Ihara S, Yamaji Y, Kinoshita H, Yamada A, Hirata Y, Hasegawa K, Sugawara Y, Kokudo N, Koike K. First case report of de novo ulcerative colitis developing after orthotopic liver transplantation successfully treated by granulocyte and monocyte apheresis. Transplant Proc 2014;46:2414-7. [PMID: 25015850 DOI: 10.1016/j.transproceed.2014.02.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 75 |
Schultheiß C, Weischenberg R, Herrmann A, Haller B, Schmid RM, Reindl W, Huber W. Dose-intensified granulocyte-monocyte apheresis in therapy refractory ulcerative colitis. Artif Organs 2015;39:187-92. [PMID: 24981894 DOI: 10.1111/aor.12329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 76 |
Rietdijk ST, D'Haens GR. Vedolizumab for the treatment of ulcerative colitis. Expert Rev Clin Pharmacol 2014;7:423-30. [PMID: 24802046 DOI: 10.1586/17512433.2014.911084] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 77 |
Yokoyama Y, Fukunaga K, Kamikozuru K, Sato T, Kawai M, Nogami K, Nagase K, Nakamura M, Immured M, Hida N, Nakamura S. Crohn's disease complicated by hepatitis B virus successfully treated with the use of adsorptive depletion of myeloid lineage leucocytes to suppress inflammatory cytokine profile. Cytotherapy 2014;16:821-5. [PMID: 24713332 DOI: 10.1016/j.jcyt.2014.01.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 78 |
Yoshino T, Nakase H, Minami N, Yamada S, Matsuura M, Yazumi S, Chiba T. Efficacy and safety of granulocyte and monocyte adsorption apheresis for ulcerative colitis: a meta-analysis. Dig Liver Dis 2014;46:219-26. [PMID: 24268950 DOI: 10.1016/j.dld.2013.10.011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 79 |
Juillerat P, Korzenik JR. Novel Nonbiologic Therapies for Ulcerative Colitis. Medical Therapy of Ulcerative Colitis 2014. [DOI: 10.1007/978-1-4939-1677-1_19] [Reference Citation Analysis]
|
| 80 |
Papi C, Fascì-Spurio F, Rogai F, Settesoldi A, Margagnoni G, Annese V. Mucosal healing in inflammatory bowel disease: treatment efficacy and predictive factors. Dig Liver Dis 2013;45:978-85. [PMID: 24018244 DOI: 10.1016/j.dld.2013.07.006] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 81 |
Sacco R, Romano A, Mazzoni A, Bertini M, Federici G, Metrangolo S, Parisi G, Nencini C, Giampietro C, Bertoni M, Tumino E, Scatena F, Bresci G. Granulocytapheresis in steroid-dependent and steroid-resistant patients with inflammatory bowel disease: a prospective observational study. J Crohns Colitis 2013;7:e692-7. [PMID: 23870727 DOI: 10.1016/j.crohns.2013.06.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 82 |
Tate D, Cairnes V, Valori R, Makins R. First successful use of leukocyte apheresis as maintenance therapy for Crohn's disease in the United Kingdom. J Clin Apher. 2014;29:181-182. [PMID: 24243700 DOI: 10.1002/jca.21308] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 83 |
Ostanin DV, Bhattacharya D. Myeloid-derived suppressor cells in the inflammatory bowel diseases. Inflamm Bowel Dis 2013;19:2468-77. [PMID: 23811636 DOI: 10.1097/MIB.0b013e3182902b11] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 84 |
Portela F, Lago P. Fulminant colitis. Best Pract Res Clin Gastroenterol 2013;27:771-82. [PMID: 24160933 DOI: 10.1016/j.bpg.2013.08.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 85 |
Sands BE, Katz S, Wolf DC, Feagan BG, Wang T, Gustofson LM, Wong C, Vandervoort MK, Hanauer S. A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease. Gut 2013;62:1288-94. [PMID: 22760005 DOI: 10.1136/gutjnl-2011-300995] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 86 |
Tanaka T, Sugiyama S, Goishi H, Kajihara T, Akagi M, Miura T. Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications. BMC Gastroenterol. 2013;13:130. [PMID: 23961883 DOI: 10.1186/1471-230x-13-130] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 87 |
Tanaka T, Sugiyama S, Goishi H, Kajihara T, Akagi M, Miura T. Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications. BMC Gastroenterol. 2013;13:130. [PMID: 23961883 DOI: 10.1016/s1873-9946(13)60351-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 88 |
Gomollón F, García-lópez S, Sicilia B, Gisbert JP, Hinojosa J. The GETECCU clinical guideline for the treatment of ulcerative colitis: A guideline created using GRADE methodology. Gastroenterología y Hepatología 2013;36:483.e1-483.e46. [DOI: 10.1016/j.gastrohep.2012.11.002] [Reference Citation Analysis]
|
| 89 |
Mehta SJ, Silver AR, Lindsay JO. Review article: strategies for the management of chronic unremitting ulcerative colitis. Aliment Pharmacol Ther 2013;38:77-97. [PMID: 23718288 DOI: 10.1111/apt.12345] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 90 |
Eberhardson M, Marits P, Jones M, Jones P, Karlen P, Karlsson M, Cotton G, Woznica K, Maltman B, Glise H, Winqvist O. Treatment of inflammatory bowel disease by chemokine receptor-targeted leukapheresis. Clin Immunol 2013;149:73-82. [PMID: 23892544 DOI: 10.1016/j.clim.2013.05.021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 91 |
Yamamoto T. The role of granulocyte and monocyte apheresis in inflammatory bowel disease. J Crohns Colitis 2013;7:e114. [PMID: 22868064 DOI: 10.1016/j.crohns.2012.07.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 92 |
Takayama T, Kanai T, Matsuoka K, Okamoto S, Sujino T, Mikami Y, Hisamatsu T, Yajima T, Iwao Y, Ogata H, Hibi T. Long-term prognosis of patients with ulcerative colitis treated with cytapheresis therapy. J Crohns Colitis 2013;7:e49-54. [PMID: 22633997 DOI: 10.1016/j.crohns.2012.05.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 93 |
Tominaga K, Nakano M, Hoshino M, Kanke K, Hiraishi H. Efficacy, safety and cost analyses in ulcerative colitis patients undergoing granulocyte and monocyte adsorption or receiving prednisolone. BMC Gastroenterol. 2013;13:41. [PMID: 23452668 DOI: 10.1186/1471-230x-13-41] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 94 |
Ramlow W, Waitz G, Sparmann G, Prophet H, Bodammer P, Emmrich J. First Human Application of a Novel Adsorptive-Type Cytapheresis Module in Patients With Active Ulcerative Colitis: A Pilot Study: Novel Apheresis Device for UC. Therapeutic Apheresis and Dialysis 2013;17:339-47. [DOI: 10.1111/1744-9987.12007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 95 |
Takahashi H, Sugawara K, Sugimura M, Iwabuchi M, Mano Y, Ukai K, Tadokoro K. Flare up of ulcerative colitis during pregnancy treated by adsorptive granulocyte and monocyte apheresis: therapeutic outcomes in three pregnant patients. Arch Gynecol Obstet. 2013;288:341-347. [PMID: 23404436 DOI: 10.1007/s00404-013-2748-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 96 |
Yokoyama Y, Kawai M, Fukunaga K, Kamikozuru K, Nagase K, Nogami K, Kono T, Ohda Y, Iimuro M, Hida N, Nakamura S, Miwa H, Matsumoto T. Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA. BMC Gastroenterol. 2013;13:27. [PMID: 23399416 DOI: 10.1186/1471-230x-13-27] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 97 |
Winters JL. Randomized controlled trials in therapeutic apheresis: Randomized Trials in Apheresis. J Clin Apheresis 2013;28:48-55. [DOI: 10.1002/jca.21263] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 98 |
Ikeda S, Takahashi H, Suga Y, Eto H, Etoh T, Okuma K, Takahashi K, Kanbara T, Seishima M, Morita A, Imai Y, Kanekura T. Therapeutic depletion of myeloid lineage leukocytes in patients with generalized pustular psoriasis indicates a major role for neutrophils in the immunopathogenesis of psoriasis. J Am Acad Dermatol 2013;68:609-17. [PMID: 23332516 DOI: 10.1016/j.jaad.2012.09.037] [Cited by in Crossref: 83] [Cited by in F6Publishing: 84] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 99 |
Vecchi M, Vernia P, Riegler G, D’Incà R, Annese V, Bagnoli S. Therapeutic landscape for ulcerative colitis: where is the Adacolumn(®) system and where should it be? Clin Exp Gastroenterol. 2013;6:1-7. [PMID: 23323022 DOI: 10.2147/ceg.s33275] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 100 |
Pham HP, Schwartz J. Therapeutic Leukocytapheresis and Adsorptive Cytapheresis. Transfusion Medicine and Hemostasis. Elsevier; 2013. pp. 511-4. [DOI: 10.1016/b978-0-12-397164-7.00076-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 101 |
Ozeki K, Tanida S, Mizoshita T, Tsukamoto H, Ebi M, Mori Y, Kataoka H, Kamiya T, Joh T. Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn’s Disease. Case Rep Gastroenterol. 2012;6:765-771. [PMID: 23341799 DOI: 10.1159/000346312] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 102 |
Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D'Haens G, D'Hoore A, Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012;6:991-1030. [PMID: 23040451 DOI: 10.1016/j.crohns.2012.09.002] [Cited by in Crossref: 728] [Cited by in F6Publishing: 749] [Article Influence: 66.2] [Reference Citation Analysis]
|
| 103 |
Shiraki M, Yamamoto T. Steroid-sparing strategies in the management of ulcerative colitis: Efficacy of leukocytapheresis. World J Gastroenterol 2012; 18(41): 5833-5838 [PMID: 23139598 DOI: 10.3748/wjg.v18.i41.5833] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 104 |
Fukunaga K, Yokoyama Y, Kamokozuru K, Nagase K, Nakamura S, Miwa H, Matsumoto T. Adsorptive granulocyte/monocyte apheresis for the maintenance of remission in patients with ulcerative colitis: a prospective randomized, double blind, sham-controlled clinical trial. Gut Liver. 2012;6:427-433. [PMID: 23170145 DOI: 10.5009/gnl.2012.6.4.427] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 105 |
Hiraoka S, Kato J, Suzuki H, Yamamoto K. Readministration of calcineurin inhibitors for ulcerative colitis. Ann Pharmacother 2012;46:1315-21. [PMID: 23032660 DOI: 10.1345/aph.1R210] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 106 |
Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2012;107:1474-82. [PMID: 22929759 DOI: 10.1038/ajg.2012.260] [Cited by in Crossref: 388] [Cited by in F6Publishing: 369] [Article Influence: 35.3] [Reference Citation Analysis]
|
| 107 |
Turner D, Levine A, Escher JC, Griffiths AM, Russell RK, Dignass A, Dias JA, Bronsky J, Braegger CP, Cucchiara S, de Ridder L, Fagerberg UL, Hussey S, Hugot JP, Kolacek S, Kolho KL, Lionetti P, Paerregaard A, Potapov A, Rintala R, Serban DE, Staiano A, Sweeny B, Veerman G, Veres G, Wilson DC, Ruemmele FM; European Crohn's and Colitis Organization, European Society for Paediatric Gastroenterology, Hepatology, and Nutrition. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr 2012;55:340-61. [PMID: 22773060 DOI: 10.1097/MPG.0b013e3182662233] [Cited by in Crossref: 278] [Cited by in F6Publishing: 294] [Article Influence: 25.3] [Reference Citation Analysis]
|
| 108 |
Kato S, Hosomi E, Amano F, Kobayashi T, Kani K, Yamamoto R, Ogawa T, Matsuda A, Sato Y, Izaki S, Mitarai T, Yakabi K. The efficacy of intensive granulocyte and monocyte adsorption apheresis in a patient with Crohn's disease complicated by extensive subcutaneous aseptic neutrophilic abscesses. J Crohns Colitis 2012;6:787-91. [PMID: 22386738 DOI: 10.1016/j.crohns.2012.02.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 109 |
C Leitner G, Worel N, Vogelsang H. Selective Granulocyte and Monocyte Apheresis as a Non-Pharmacological Option for Patients with Inflammatory Bowel Disease. Transfus Med Hemother 2012;39:246-52. [PMID: 22969694 DOI: 10.1159/000341801] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 110 |
Fukunaga K, Matsumoto T. Current status and future perspectives of leukocytapheresis for inflammatory bowel disease. J Gastroenterol Hepatol 2012;27:997-1003. [PMID: 22414250 DOI: 10.1111/j.1440-1746.2012.07119.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 111 |
Sono K, Yamada A, Yoshimatsu Y, Takada N, Suzuki Y. Factors associated with the loss of response to infliximab in patients with Crohn's disease. Cytokine 2012;59:410-6. [PMID: 22633084 DOI: 10.1016/j.cyto.2012.04.026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 112 |
Cabriada JL, Domènech E, Ibargoyen N, Hernández V, Clofent J, Ginard D, Gutiérrez-Ibarluzea I, Hinojosa J. Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry. J Gastroenterol 2012;47:359-65. [PMID: 22105230 DOI: 10.1007/s00535-011-0499-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 113 |
Ostanin DV, Kurmaeva E, Furr K, Bao R, Hoffman J, Berney S, Grisham MB. Acquisition of antigen-presenting functions by neutrophils isolated from mice with chronic colitis. J Immunol 2012;188:1491-502. [PMID: 22219329 DOI: 10.4049/jimmunol.1102296] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 114 |
Cabriada JL. Aféresis en enfermedad inflamatoria intestinal. ¿Una opción válida? Gastroenterología y Hepatología 2012;35:22-31. [DOI: 10.1016/j.gastrohep.2011.10.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 115 |
Flanagan P, Leiper K. Medical Management of Ulcerative Colitis. Contemporary Coloproctology 2012. [DOI: 10.1007/978-0-85729-889-8_17] [Reference Citation Analysis]
|
| 116 |
Yoshimura N, Tadami T, Kawaguchi T, Sako M, Yoshimoto H, Yamaka T, Takazoe M. Processed blood volume impacts clinical efficacy in patients with ulcerative colitis undergoing adsorptive depletion of myeloid lineage leucocytes. J Gastroenterol 2012;47:49-55. [PMID: 21915624 DOI: 10.1007/s00535-011-0464-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 117 |
Vavricka S. Granulocyte-monocyte apheresis - not the end of the road yet! Digestion 2011;84:1-2. [PMID: 21311189 DOI: 10.1159/000322434] [Reference Citation Analysis]
|
| 118 |
Kato S, Kobayashi T, Kani K, Takabayashi H, Yamamoto R, Yakabi K. Elevated serum IgE prior to acute severe infusion reaction during infliximab maintenance therapy in a Crohn's disease patient. Inflamm Bowel Dis 2011;17:E156-7. [PMID: 21898702 DOI: 10.1002/ibd.21857] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 119 |
Fukunaga K, Kamikozuru K, Yokoyama Y, Hida N, Ohda Y, Takeda N, Yoshida K, Iimuro M, Kikuyama R, Kato K, Nagase K, Nakamura S, Miwa H, Matsumoto T. Optimal apheresis treatment volume for the efficacy and safety of leukocytapheresis with cellsorba in patients with active ulcerative colitis. J Clin Apheresis 2011;26:326-31. [DOI: 10.1002/jca.20314] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 120 |
Passalacqua S, Ferraro PM, Bresci G, D'Ovidio V, Astegiano M, Principi M, Testa R, D'Incà R, Valpiani D, Armuzzi A, Sablich R, Cavallaro F, Costa F, Di Leo V, Colombo E, Santini A, Aratari A, Lecis P, Saladino V, Riegler G, Marco M, Calella F, Ricci C, Guidi ML, Repaci G, Silla M. The Italian Registry of Therapeutic Apheresis: granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study. J Clin Apher 2011;26:332-7. [PMID: 22072543 DOI: 10.1002/jca.20315] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 121 |
Kikuyama R, Fukunaga K, Kawai M, Yokoyama Y, Kamikozuru K, Hida N, Ohda Y, Takeda N, Yoshida K, Iimuro M, Kato K, Kono T, Nogami K, Nagase K, Nakamura S, Takei Y, Miwa H, Matsumoto T. Relevance of the Processed Blood Volume per Granulocyte and Monocyte Apheresis Session to its Clinical Efficacy in Patients With Ulcerative Colitis: Bodyweight Oriented GMA in UC Patients. Therapeutic Apheresis and Dialysis 2011;15:360-6. [DOI: 10.1111/j.1744-9987.2011.00968.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 122 |
Zhu M, Xu X, Nie F, Tong J, Xiao S, Ran Z. The efficacy and safety of selective leukocytapheresis in the treatment of ulcerative colitis: a meta-analysis. Int J Colorectal Dis 2011;26:999-1007. [PMID: 21476027 DOI: 10.1007/s00384-011-1193-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 123 |
Moribata K, Kato J, Iimura S, Yoshida S, Shingaki N, Ueda K, Deguchi H, Inoue I, Maekita T, Iguchi M, Tamai H, Ichinose M. Mucosal healing of esophageal involvement of Crohn's disease with granulocyte/monocyte adsorption. J Clin Apher 2011;26:225-7. [PMID: 21786316 DOI: 10.1002/jca.20295] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 124 |
Meier J, Sturm A. Current treatment of ulcerative colitis. World J Gastroenterol 2011; 17(27): 3204-3212 [PMID: 21912469 DOI: 10.3748/wjg.v17.i27.3204] [Cited by in F6Publishing: 49] [Reference Citation Analysis]
|
| 125 |
Terao S, Yamashiro K, Tamura I, Hirano T, Ohkusa T, Kato K. Antibiotic combination therapy for steroid withdrawal in steroid-dependent ulcerative colitis. Digestion 2011;83:198-203. [PMID: 21266816 DOI: 10.1159/000321811] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 126 |
D'Ovidio V, Meo D, Viscido A, Bresci G, Vernia P, Caprilli R. Predictive factors of clinical response in steroid-refractory ulcerative colitis treated with granulocyte-monocyte apheresis. World J Gastroenterol 2011; 17(14): 1831-1835 [PMID: 21528055 DOI: 10.3748/wjg.v17.i14.1831] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 127 |
Williams I, Goh J. Investigational new drugs in the treatment of inflammatory bowel disease: a review. J Exp Pharmacol. 2011;3:13-19. [PMID: 27186106 DOI: 10.2147/jep.s7806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 128 |
Vernia P, D’Ovidio V, Meo D. Leukocytapheresis in the treatment of inflammatory bowel disease: Current position and perspectives. Transfus Apher Sci. 2010;43:227-229. [PMID: 20817610 DOI: 10.1016/j.transci.2010.07.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 129 |
Naganuma M, Fujii T, Watanabe M. The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. J Gastroenterol 2011;46:129-37. [PMID: 21132334 DOI: 10.1007/s00535-010-0352-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 130 |
Ng SC, Chan FK, Sung JJ. Review article: the role of non-biological drugs in refractory inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:417-27. [PMID: 21138457 DOI: 10.1111/j.1365-2036.2010.04541.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 131 |
Yamamoto T. Granulocyte and monocyte adsorptive apheresis in the management of ulcerative colitis. Aliment Pharmacol Ther 2011;33:288; author reply 289. [PMID: 21155856 DOI: 10.1111/j.1365-2036.2010.04521.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 132 |
Thanaraj S, Hamlin PJ, Ford AC. Systematic review: granulocyte/monocyte adsorptive apheresis for ulcerative colitis. Aliment Pharmacol Ther 2010;32:1297-306. [PMID: 21050231 DOI: 10.1111/j.1365-2036.2010.04490.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 133 |
Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, Lofberg R. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol. 2011;163:50-58. [PMID: 21078086 DOI: 10.1111/j.1365-2249.2010.04279.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 72] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 134 |
Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, Lofberg R. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol 2011;163:50-8. [PMID: 21078086 DOI: 10.1111/j.1365-2249.2010.04279.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 135 |
Saniabadi AR, Hanai H. Therapeutic apheresis from the early civilizations to the twenty-first century. Gastroenterol Clin Biol 2010;34:645-8. [PMID: 20971590 DOI: 10.1016/j.gcb.2010.09.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 136 |
Nosé Y. Leukocyte removal and its effects on immunomodulation. Artif Organs 2010;34:451-2. [PMID: 20624159 DOI: 10.1111/j.1525-1594.2010.01043.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 137 |
Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz BH; Apheresis Applications Committee of the American Society for Apheresis. Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2010;25:83-177. [PMID: 20568098 DOI: 10.1002/jca.20240] [Cited by in Crossref: 385] [Cited by in F6Publishing: 412] [Article Influence: 29.6] [Reference Citation Analysis]
|
| 138 |
Tanaka T, Okanobu H, Kuga Y, Yoshifuku Y, Fujino H, Miwata T, Moriya T, Nishida T, Oya T. Clinical and endoscopic features of responders and non-responders to adsorptive leucocytapheresis: a report based on 120 patients with active ulcerative colitis. Gastroenterol Clin Biol. 2010;34:687-695. [PMID: 20934287 DOI: 10.1016/j.gcb.2010.08.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 139 |
Jewell DP, Sutherland LR, Mcdonald JW, Feagan BG. Ulcerative Colitis. Evidence‐Based Gastroenterology and Hepatology 2010. [DOI: 10.1002/9781444314403.ch12] [Reference Citation Analysis]
|
| 140 |
Lindberg A, Eberhardson M, Karlsson M, Karlén P. Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease. BMC Gastroenterol. 2010;10:73. [PMID: 20604939 DOI: 10.1186/1471-230x-10-73] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 141 |
Takeda S, Sato T, Katsuno T, Nakagawa T, Noguchi Y, Yokosuka O, Saito Y. Adsorptive depletion of alpha4 integrin(hi)- and CX3CR1hi-expressing proinflammatory monocytes in patients with ulcerative colitis. Dig Dis Sci 2010;55:1886-95. [PMID: 19908144 DOI: 10.1007/s10620-009-0974-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 142 |
Ibargoyen-Roteta N, Gutiérrez-Ibarluzea I, Rico-Iturrioz R, López-Argumedo M, Reviriego-Rodrigo E, Cabriada-Nuño JL, Schünemann HJ. The GRADE approach for assessing new technologies as applied to apheresis devices in ulcerative colitis. Implement Sci 2010;5:48. [PMID: 20553616 DOI: 10.1186/1748-5908-5-48] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 143 |
Dignass AU, Eriksson A, Kilander A, Pukitis A, Rhodes JM, Vavricka S. Clinical trial: five or ten cycles of granulocyte-monocyte apheresis show equivalent efficacy and safety in ulcerative colitis. Aliment Pharmacol Ther 2010;31:1286-95. [PMID: 20331579 DOI: 10.1111/j.1365-2036.2010.04295.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 144 |
Thanaraj S, Hamlin PJ, Ford AC. Is the benefit of granulocyte monocyte adsorptive apheresis in ulcerative colitis overstated? Dig Dis Sci 2010;55:1803; author reply 1803-4. [PMID: 20431950 DOI: 10.1007/s10620-010-1188-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 145 |
Cabriada JL, Ibargoyen N, Hernández A, Bernal A, Castiella A. Sustained remission after steroids and leukocytapheresis induced response in steroid-dependent ulcerative colitis: results at 1 year. Dig Liver Dis 2010;42:432-5. [PMID: 19833566 DOI: 10.1016/j.dld.2009.09.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 146 |
Habermalz B, Sauerland S. Clinical effectiveness of selective granulocyte, monocyte adsorptive apheresis with the Adacolumn device in ulcerative colitis. Dig Dis Sci 2010;55:1421-8. [PMID: 19517236 DOI: 10.1007/s10620-009-0845-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 147 |
Miyamoto H, Sugita Y, Motomura T, Ohta K, Nosé Y. Preliminary studies for the development of a second generation granulocytapheresis (G-CAP) column. J Artif Organs 2010;13:92-6. [PMID: 20364286 DOI: 10.1007/s10047-010-0498-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 148 |
Ooi CJ, Fock KM, Makharia GK, Goh KL, Ling KL, Hilmi I, Lim WC, Kelvin T, Gibson PR, Gearry RB, Ouyang Q, Sollano J, Manatsathit S, Rerknimitr R, Wei SC, Leung WK, de Silva HJ, Leong RW; Asia Pacific Association of Gastroenterology Working Group on Inflammatory Bowel Disease. The Asia-Pacific consensus on ulcerative colitis. J Gastroenterol Hepatol 2010;25:453-68. [PMID: 20370724 DOI: 10.1111/j.1440-1746.2010.06241.x] [Cited by in Crossref: 111] [Cited by in F6Publishing: 104] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 149 |
Yamaguchi T, Yoshida S, Tanaka S, Takemura Y, Oka S, Yoshihara M, Yamada H, Chayama K. Predicting the clinical response to cytapheresis in steroid-refractory or -dependent ulcerative colitis using contrast-enhanced ultrasonography. Scand J Gastroenterol 2009;44:831-7. [PMID: 19811342 DOI: 10.1080/00365520902839659] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 150 |
Osterman MT, Lichtenstein GR. Ulcerative Colitis. Sleisenger and Fordtran's Gastrointestinal and Liver Disease 2010. [DOI: 10.1016/b978-1-4160-6189-2.00112-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 151 |
Sakuraba A, Motoya S, Watanabe K, Nishishita M, Kanke K, Matsui T, Suzuki Y, Oshima T, Kunisaki R, Matsumoto T, Hanai H, Fukunaga K, Yoshimura N, Chiba T, Funakoshi S, Aoyama N, Andoh A, Nakase H, Mizuta Y, Suzuki R, Akamatsu T, Iizuka M, Ashida T, Hibi T. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol 2009;104:2990-5. [PMID: 19724269 DOI: 10.1038/ajg.2009.453] [Cited by in Crossref: 102] [Cited by in F6Publishing: 107] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 152 |
Mcleod BC. Therapeutic apheresis: history, clinical application, and lingering uncertainties: THERAPEUTIC APHERESIS. Transfusion 2010;50:1413-26. [DOI: 10.1111/j.1537-2995.2009.02505.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 153 |
Pastorelli L, Pizarro TT, Cominelli F, Vecchi M. Emerging drugs for the treatment of ulcerative colitis. Expert Opin Emerg Drugs 2009;14:505-21. [PMID: 19656075 DOI: 10.1517/14728210903146882] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 154 |
Mitsuyama K, Sata M. Therapeutic leukocytapheresis in inflammatory bowel disease: clinical efficacy and mechanisms of action. Cytotherapy. 2009;11:229-237. [PMID: 19241197 DOI: 10.1080/14653240902725566] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 155 |
Martín-Carpi J, Varea V. Clinical, endoscopic and histological remission in paediatric chronically active ulcerative colitis after prolonged treatment with selective granulocyte-monocyte adsorptive apheresis. J Crohns Colitis 2009;3:216-7. [PMID: 21172276 DOI: 10.1016/j.crohns.2009.03.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 156 |
Arseneau KO, Cominelli F. Leukocytapheresis in ulcerative colitis: a possible alternative to biological therapy? Dig Liver Dis 2009;41:551-2. [PMID: 19540820 DOI: 10.1016/j.dld.2009.05.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 157 |
Nos P, Domènech E. Tratamiento con aféresis en la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2009;32:509-18. [DOI: 10.1016/j.gastrohep.2009.01.183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 158 |
Hibi T, Sameshima Y, Sekiguchi Y, Hisatome Y, Maruyama F, Moriwaki K, Shima C, Saniabadi AR, Matsumoto T. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. Dig Liver Dis 2009;41:570-7. [PMID: 19211314 DOI: 10.1016/j.dld.2008.11.020] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 159 |
Ng SC, Kamm MA. Therapeutic strategies for the management of ulcerative colitis. Inflamm Bowel Dis 2009;15:935-50. [PMID: 18985710 DOI: 10.1002/ibd.20797] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 160 |
Fukunaga K, Nagase K, Kusaka T, Hida N, Ohda Y, Yoshida K, Tozawa K, Kamikozuru K, Iimuro M, Nakamura S, Miwa H, Matsumoto T. Cytapheresis in patients with severe ulcerative colitis after failure of intravenous corticosteroid: a long-term retrospective cohort study. Gut Liver 2009;3:41-7. [PMID: 20479900 DOI: 10.5009/gnl.2009.3.1.41] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 161 |
Matsuda R, Koide T, Tokoro C, Yamamoto T, Godai T, Morohashi T, Fujita Y, Takahashi D, Kawana I, Suzuki S, Umemura S. Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naïve ulcerative colitis during active and quiescent disease. Inflamm Bowel Dis 2009;15:328-34. [PMID: 18942752 DOI: 10.1002/ibd.20759] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 162 |
Ghosh S, Kaplan G, Panaccione R. Granulocyte–monocyte apheresis for the treatment of ulcerative colitis—is this the end of the road? Nat Rev Gastroenterol Hepatol 2009;6:6-7. [DOI: 10.1038/ncpgasthep1299] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 163 |
Sigurbjörnsson FT, Bjarnason I. Leukocytapheresis for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol. 2008;5:509-516. [PMID: 18665138 DOI: 10.1038/ncpgasthep1209] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 164 |
Edinger M. CD4+ CD25+ regulatory T cells approach the clinic. Cytotherapy 2008;10:655-6. [DOI: 10.1080/14653240802492705] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
